1. Introduction {#sec1-ijms-16-23035}
===============

Pre-eclampsia (PE) is an important cause of perinatal morbidity and mortality and complicates 2%--8% of pregnancies \[[@B1-ijms-16-23035]\]. Worldwide, PE is responsible for more than 50,000 maternal deaths annually \[[@B2-ijms-16-23035],[@B3-ijms-16-23035]\]. It is characterized by *de novo* hypertension and proteinuria after 20 weeks of gestation. However, PE continues to cause diagnostic dilemmas due to the heterogeneity of its clinical presentations. Clinical phenotypes range from early-onset severe hypertension accompanied by fetal growth restriction and its consequences to late-onset mild hypertension with a normally grown (or even macrosomic) fetus and few long-term complications. The concept that PE may involve several subtypes is now emerging in the literature. It is thought that the end clinical presentation may be due to the maternal response to abnormal placentation or placental function \[[@B4-ijms-16-23035]\].

As PE cannot be predicted by previous obstetric history and risk factors alone \[[@B5-ijms-16-23035]\], much research has focused on the identification of women at high risk of developing PE. This would allow more intensive monitoring of this high risk group as well as targeted prophylactic intervention, timely diagnosis and treatment. The identification of PE biomarkers in early pregnancy would enable appropriate stratification of a pregnancy into high and low risk, such that a positive predictive test would allow specific therapeutic interventions. Maternal deaths due to PE might thus be avoided more easily as the ultimate long term goal \[[@B6-ijms-16-23035]\]. However, on a pragmatic basis, the identification of PE biomarkers would lead to increased maternal surveillance of high risk pregnancies and improve perinatal outcomes.

Due to the complex pathophysiology and aetiology of PE, a wide range of potential biomarkers have been investigated \[[@B7-ijms-16-23035]\]. These biomarkers can be classified under different categories and many novel biomolecules have been identified. In addition to the predictive value of biomarkers, the identification of these entities (e.g., metabolomic or proteiomic molecules) may elucidate the underlying mechanism for the pathogenesis of PE. Although no single biomarker has been deemed suitable for clinical application at present \[[@B8-ijms-16-23035]\] various novel biomarkers or combinations of biomarkers with other well recognized clinical parameters are promising. To this end, we conducted a systematic review and meta-analyses of biomarkers during the first half of pregnancy for the prediction of PE.

2. Results {#sec2-ijms-16-23035}
==========

Of the 1716 identified articles, 147 articles were included following full screening. The study selection process is illustrated in [Figure 1](#ijms-16-23035-f001){ref-type="fig"}, while the overall result of the QUADAS-2 quality assessment is shown in [Figure 2](#ijms-16-23035-f002){ref-type="fig"}. [Figure 3](#ijms-16-23035-f003){ref-type="fig"} demonstrates the frequency of the different laboratory biomarkers in all included studies (401 laboratory biomarkers were described in 147 studies). Placental growth factor (PlGF), pregnancy associated plasma protein A (PAPP-A), soluble fms-like tyrosine kinase (sFLT) and placental protein 13 (PP-13) were the most commonly studied biomarkers.

![Flowchart of selection process. GA: gestational age.](ijms-16-23035-g001){#ijms-16-23035-f001}

![QUADAS-2 Quality score. QUADAS: Quality Assessment of Diagnostic Accuracy Studies.](ijms-16-23035-g002){#ijms-16-23035-f002}

![Distribution of studied laboratory biomarkers (*n* = 401) in included articles (*n* = 147). PlGF: Placental growth factor; PAPP-A: Pregnancy associated plasma protein A; PP-13: Placental protein 13; ADAM-12: a disintegrin and metalloprotease 12; CRP: C-reactive protein; sFlt: Soluble fms-like tyrosine kinase-1; MMP-9: Matrix metallopeptidase 9; TNF-R1: Tumour-necrosis factor receptor-1; VEGF: Vascular endothelial growth factor; VEGFR: Vascular endothelial growth factor receptor; SHBG: Sex hormone-binding globulin.](ijms-16-23035-g003){#ijms-16-23035-f003}

We were able to extract sensitivity and specificity from 36 studies for all PE, 10 studies for EOPE and 7 studies for LOPE; we performed a meta-analyses of all single biomarkers and of the reported combination of biomarkers separately. We performed separate meta-analyses for the following biomarkers (\>2 studies available): a disintegrin and metalloprotease 12 (ADAM-12), inhibin-A, PAPP-A, PlGF, PP-13. The characteristics of the included studies are shown in [Table 1](#ijms-16-23035-t001){ref-type="table"}.

ijms-16-23035-t001_Table 1

###### 

General characteristics of the included studies in the meta-analyses. GH: gestational hypertension; SGA: small for gestational age. PTB: preterm birth. The outcomes used were in line with the definitions from International Society for the study of Hypertension (ISSHP) \[[@B9-ijms-16-23035]\].

  Study                                             Year   GA of Test (Weeks)     Biomarker (s)                                                        Outcome                         Study Design ^A^                                                  Low/High Risk   Location               *n* (Total)   *n* (PE)   Level of Evidence
  ------------------------------------------------- ------ ---------------------- -------------------------------------------------------------------- ------------------------------- ----------------------------------------------------------------- --------------- ---------------------- ------------- ---------- -------------------
  Anderson *et al*. \[[@B10-ijms-16-23035]\]        2011   11--16                 α-1-microglobulin and fetal hemoglobin                               PE                              Nested case control (in prospective study) ^1^                    LR              UK                     96            60         3b
  Akolekar *et al*. \[[@B11-ijms-16-23035]\]        2008   11--14                 PlGF, PAPP-A                                                         EOPE, LOPE, GH                  Nested case-control (in trisomy 21 screening cohort) ^2^          LR + HR         UK                     824           127        3b
  Akolekar *et al*. \[[@B12-ijms-16-23035]\]        2013   11--14                 PlGF, PAPP-A                                                         PE                              Prospective cohort (in screening)                                 LR + HR         UK                     58,703        1245       1b
  Audibert *et al*. \[[@B13-ijms-16-23035]\]        2010   11--13                 PAPP-A, ADAM-12, PlGF, hCG, inhibin-A, PP-13, protein-A, inhibin-A   PE, EOPE, LOPE, GH              Prospective cohort (trisomy 21 screening cohort) ^3^              LR + HR         Canada                 893           40         1b
  Bills *et al*. \[[@B14-ijms-16-23035]\]           2009   First trimester        VEGF(165)b, sFLT, sEng                                               PE, EOPE, LOPE                  Case-control ^4^                                                  LR + HR         UK                     70            25         3b
  Bosio *et al*. \[[@B15-ijms-16-23035]\]           2001   10--14                 P-selectin                                                           PE, GH                          Nested case-control (in longitudinal cohort) ^5^                  LR + HR         Ireland                70            20         3b
  Boucoiran *et al*. (1) \[[@B16-ijms-16-23035]\]   2013   12--18                 PlGF, sFlt-1, inhibin A                                              PE, GH, SGA                     Prospective cohort (nested in RCT) ^6^                            LR + HR         Canada                 793           34         1b
  Boucoiran *et al.* (2) \[[@B17-ijms-16-23035]\]   2013   11-14 and 18-22        PlGF, PP-13, ADAM-12                                                 EOPE, LOPE, GH                  Prospective cohort (trisomy 21 screening cohort) ^7^              LR + HR         Canada                 893           40         1b
  Brameld *et al*. \[[@B18-ijms-16-23035]\]         2008   12 + 3                 PAPP-A, free-hCG                                                     PE                              Retrospective cohort (trisomy 21 screening cohort) ^8^            LR              Australia              22,125        660        2b
  Chafetz *et al*. \[[@B19-ijms-16-23035]\]         2007   9--12                  PP-13                                                                PE, PTB, SGA                    Nested case control in prospective cohort (MOMS-study) ^9^        LR              USA                    425           47         3b
  Cohen *et al*. \[[@B20-ijms-16-23035]\]           2014   10--13                 PAPP-A, α fetoprotein, free β-hCG                                    PE                              Nested case control (retrospective cohort) ^10^                   LR + HR         USA                    2199          148        3b
  Cowans *et al.* \[[@B21-ijms-16-23035]\]          2011   11--14                 PP-13                                                                EOPE, LOPE                      Nested case control (in cohort of trisomy screening) ^11^         HR              UK                     234           37         3b
  Deurloo *et al*. \[[@B22-ijms-16-23035]\]         2013   9--14                  ADAM-12, PP-13                                                       PE, GH, SGA                     Nested case control (in cohort of trisomy screening ^12^          LR + HR         The Netherlands        220           17         3b
  Dugoff *et al.* \[[@B23-ijms-16-23035]\]          2004   10--14                 PAPP-A                                                               PE, PTB, SGA                    Prospective study (FASTER trial, trisomy screening cohort) ^13^   LR              USA                    34,271        764        1b
  Giguere *et al*. \[[@B24-ijms-16-23035]\]         2014   10--18                 PlGF, sFlt, PAPP-A, inhibin-A                                        PE                              Nested case-control (in prospective cohort) ^14^                  LR              Canada                 648           216        3b
  Goetzinger *et al*. \[[@B25-ijms-16-23035]\]      2013   11--14                 ADAM-12, PAPP-A                                                      PE, EOPE, LOPE                  Prospective cohort ^15^                                           LR + HR         USA                    578           54         1b
  Gonen *et al.* \[[@B26-ijms-16-23035]\]           2008   6--10                  PP-13                                                                PE, GH                          Prospective cohort ^16^                                           LR + HR         Israel                 1239          20         1b
  Ghosh *et al*. \[[@B27-ijms-16-23035]\]           2013   11--14                 PlGF                                                                 EOPE                            Prospective study (screening antenatal care) ^17^                 LR + HR         India                  1206          9          1b
  Hedley *et al*. \[[@B28-ijms-16-23035]\]          2010   10--14                 PAPP-A, free leptin index                                            PE                              Nested case control (in First Trimester Screening Study) ^18^     LR              Denmark                415           126        3b
  Kang *et al*. \[[@B29-ijms-16-23035]\]            2008   11 and 16              PAPP-A, AFP, uE3, hCG, inhibin-A                                     PE                              Retrospective cohort (trisomy 21 screening cohort) ^19^           LR + HR         Korea                  3076          32         2b
  Kenny *et al*. \[[@B30-ijms-16-23035]\]           2014   14--16                 Multiple                                                             PE, EOPE, preterm and term PE   Prospective cohort ^20^                                           LR              Australia/UK/Ireland   5623          278        1b
  Khalil *et al*. \[[@B31-ijms-16-23035]\]          2010   11--14                 PP-13                                                                PE, EOPE, PE + SGA              Nested case-control (in antenatal clinic cohort) ^21^             HR              UK                     252           42         3b
  Kuc *et al.* \[[@B32-ijms-16-23035]\]             2013   9--14                  PAPP-A, free -hCG, ADAM-12, PlGF                                     EOPE, LOPE                      Nested case control (in screening cohort) ^22^                    LR + HR         The Netherlands        667           167        3b
  Kusanovic *et al.* \[[@B33-ijms-16-23035]\]       2009   6--15                  PlGF, soluble endoglin, sVEGFR-1                                     EOPE, LOPE                      Prospective cohort ^23^                                           LR              Chile                  1622          62         3b
  Myatt *et al*. \[[@B34-ijms-16-23035]\]           2012   9--13                  ADAM-12, PAPP-A, PP-13, sFLT, endoglin                               PE                              Nested case control (in cohort of RCT) ^24^                       LR              USA                    683           174        2b
  Myers *et al*. \[[@B35-ijms-16-23035]\]           2013   14--16                 PlGF, soluble endoglin, sFLT-1                                       preterm PE (\<37 week)          Prospective cohort ^25^                                           LR              Australia/UK/Ireland   235           47         1b
  Nicolaides *et al.* \[[@B36-ijms-16-23035]\]      2006   11--14                 PP-13                                                                EOPE                            Nested case control (in screening cohort) ^26^                    LR + HR         UK                     433           10         3b
  Odibo *et al.* \[[@B37-ijms-16-23035]\]           2011   11--14                 PP13, PAPP-A                                                         PE, EOPE                        Prospective cohort (trisomy 21 screening cohort) ^27^             LR + HR         USA                    452           42         1b
  Park *et al*. \[[@B38-ijms-16-23035]\]            2014   11--14                 PAPP-A, PlGF, inhibin-A, sFLT                                        LOPE                            Prospective cohort ^28^                                           LR              Korea                  262           8          1b
  Poon *et al*. (1) \[[@B39-ijms-16-23035]\]        2009   11--14                 PAPP-A                                                               PE, EOPE, LOPE                  Prospective cohort (trisomy 21 screening cohort) ^29^             LR + HR         UK                     8051          156        1b
  Poon *et al*. (2) \[[@B40-ijms-16-23035]\]        2009   11--14                 PAPP-A, MMP-9, TNF-R1                                                EOPE, LOPE, GH, SGA, PTB        Nested case-control (in trisomy 21 screening cohort) ^30^         LR + HR         UK                     1138          128        3b
  Roes *et al*. \[[@B41-ijms-16-23035]\]            2004   6--15                  Inhibin-A                                                            PE                              Case control ^31^                                                 LR              The Netherlands        55            19         3b
  Schneuer *et al*. \[[@B42-ijms-16-23035]\]        2012   11--13                 PP-13                                                                PE, EOPE, LOPE, SGA             Prospective cohort (trisomy 21 screening cohort) ^32^             LR + HR         Australia              2678          71         1b
  Spencer *et al*. \[[@B43-ijms-16-23035]\]         2006   11--14                 PP-13, PAPP-A                                                        PE, EOPE, LOPE                  Nested case-control (in trisomy 21 screening cohort) ^33^         LR              UK                     534           88         3b
  Spencer *et al.* \[[@B44-ijms-16-23035]\]         2008   11--14                 Inhibin-A and activin-A                                              PE, EOPE, LOPE                  Nested case-control (in trisomy 21 screening cohort) ^34^         LR              UK                     304           64         3b
  Tidwell *et al*. \[[@B45-ijms-16-23035]\]         2001   5--15                  PlGF                                                                 EOPE, LOPE                      Case control ^35^                                                 LR              Taiwan                 39            14         3b
  Thilaganathan *et al*. \[[@B46-ijms-16-23035]\]   2010   14.7 (CO), 16.3 (PE)   cystatin-C, CRP                                                      PE                              Nested case-control (in antenatal clinic cohort) ^36^             LR              UK                     170           45         3b
  Xu *et al.* \[[@B47-ijms-16-23035]\]              2014   First trimester        Chemerin                                                             PE                              Prospective cohort (antenatal care)^37^                           LR              China                  518           41         1b
  Youssef *et al.* \[[@B48-ijms-16-23035]\]         2011   11--14                 PAPP-A, PlGF, sFlt-1, P-selectin, NGAL                               LOPE                            Prospective cohort ^38^                                           LR + HR         Italy                  528           13         1b
  Yu *et al.* \[[@B49-ijms-16-23035]\]              2011   12--16                 PlGF, inhibin-A, activin-A                                           PE                              Nested case-control (in antenatal clinic cohort) ^39^             LR              China                  124           31         3b
  Zong *et al.* \[[@B50-ijms-16-23035]\]            2012   13--16                 Htr-A1 (High-Temperature Requirement A1)                             PE                              Prospective cohort (clinical cohort) ^40^                         LR              China                  1396          100        1b

^A^ Characteristics of the study population are mentioned below; ^1^ Exclusion criteria diabetes, prepregnancy hypertension and premature delivery; ^2^ Controls: did not develop any pregnancy complications and resulted in the live birth of phenotypically normal neonates; ^3^ Exclusion: multiparous, multiple gestation, major fetal chromosomal/structural anomaly; ^4^ Exclusion: pregnancy induced hypertension, fetal growth restriction, intrauterine death, preterm birth (PTB); ^5^ Controls: normal obstetric outcome. Matched for body mass index (BMI); ^6^ Exclusion: vitamin C and/or vitamin E supplements, history of major medical complications, major fetal defects, repeated spontaneous abortion, use of an illicit drug or warfarin treatment during the current pregnancy; ^7^ Inclusion: nulliparous women with singleton pregnancies without major fetal chromosomal or structural anomaly; ^8^ Exclusion: Women who had a previous fetus with a chromosomal abnormality and women with insulin-dependent diabetes mellitus; ^9^ Exclusion: AIDS or hepatitis, cases of major fetal anomaly, fetal death and women with placenta previa, placenta accrete, or placental abruption; ^10^ General population, singleton pregnancies; ^11^ A priori high risk pregnancies; ^12^ General population; ^13^ Inclusion: singleton pregnancy, exclusion: diabetes and chromosomal abnormalities; ^14^ Exclusion: chronic hepatic or renal diseases, pregnancies with major fetal abnormalities and those ending in termination, miscarriage or fetal death \<24 weeks; ^15^ Exclusion : known aneuploidy and major congenital malformations; ^16^ Exclusion: miscarriages; ^17^ Exclusion: congenital abnormalities or medication use; ^18^ Randomly selected controls; ^19^ Exclusion: multifetal gestation, diabetes, chromosomal or structural abnormalities; ^20^ Exclusion: increased risk factors of PE, SGA or PTB, known major fetal anomaly or abnormal karyotype, intervention that may modify pregnancy outcome such as treatment with aspirin or progesterone; ^21^ Inclusion: history of PE in a previous pregnancy, chronic hypertension, chronic renal disease, antiphospholipid syndrome, systemic lupus erythematosus, pregestational diabetes mellitus, obesity (BMI ≥ 30 kg/m^2^). Exclusion: multiple pregnancy, cases of major fetal anomaly, miscarriage or fetal death, HIV or hepatitis, placenta previa or placental abruption; ^22^ Exclusion: multiple pregnancy, delivery \<24 weeks, chromosomal abnormalities; ^23^ Inclusion: pregnancies in which a single live fetus was delivered after 37 complete weeks of gestation with birth weight above the 10th centile and without fetal anomalies; ^24^ Inclusion: nulliparous, low risk women; ^25^ Exclusion: increased risk of PE, SGA or PTB, known major fetal anomaly or abnormal karyotype, intervention that may modify pregnancy outcome such as treatment with aspirin or progesterone; ^26^ Gestational age matched controls; ^27^ Inclusion : singleton pregnancies. Exclusion: spontaneous miscarriage prior to 20 weeks, loss to follow-up or fetal anomalies diagnosed in the second trimester; ^28^ Exclusion: high risk pregnancies; ^29^ Definition controls: randomly selected women without reported pregnancy-associated hypertension; ^30^ Definition controls: had blood collected and stored on the same day, which did not develop any pregnancy complications and resulted in the live birth of phenotypically normal neonates; ^31^ Unknown in- and exclusion criteria; ^32^ Inclusion: singleton pregnancies; ^33,34^ Gestational age matched controls; ^35^ Exclusion: multiparity, chronic hypertension, diabetes, multiple gestation, connective tissue disorder, any long-term use of medicine other than prenatal vitamins, and miscarriage before viability; ^36^ Exclusion: diabetes, connective tissue disease, renal disorders, essential hypertension; ^37^ Exclusion: previous systemic disorders or drug use, chronic hypertension, diabetes, renal disorders, recent or present fever or infectious disease, malignancies, autoimmune diseases and multiple pregnancies; ^38^ Exclusion: early-onset PE, multiple gestations, pregnancies with fetal chromosomal or major structural anomaly, miscarriages; ^39^ Unknown inclusion/exclusion criteria; ^40^ Exclusion: cases showing intrahepatic cholestasis of pregnancy, abortion, peripartum cardiomyopathy, and other complications. PlGF: Placental growth factor; PAPP-A: Pregnancy associated plasma protein A; ADAM-12: A disintegrin and metalloprotease 12; CRP: C-reactive protein; hCG: human chorionic gonadotropin; PP-13: Placental protein 13; VEGF: Vascular endothelial growth factor; sFLT: Soluble fms-like tyrosine kinase-1; sEng: Soluble endoglin; sVEGR-1: Soluble endothelial growth factor-1; uE3: Oestradiol; MMP-9: Matrix metallopeptidase 9; TNF-R1: Tumor-necrosis factor receptor-1; NGAL: Neutrophil gelatinase-associated lipocalin; (1): publication 1 by same author in same year; (2): publication 2 by same author in same year.

2.1. PE {#sec2dot1-ijms-16-23035}
-------

In studies which analysed women with PE without sub-classifying into EOPE and LOPE, the pooled sensitivity of all single biomarkers (*n* = 66) was 0.40 (95% CI 0.39--0.41, I^2^ 96.9%) at a false positive rate of 10% ([Figure 4](#ijms-16-23035-f004){ref-type="fig"}). The area under the SROC was 0.786 (SE 0.02) ([Figure 5](#ijms-16-23035-f005){ref-type="fig"}). The pooled sensitivity, specificity and area under the SROC of the separate meta-analyses of ADAM-12, inhibin-A, PAPP-A, PlGF and PP-13 are shown in [Table 2](#ijms-16-23035-t002){ref-type="table"}. All these meta-analyses showed a high heterogeneity (I^2^ \> 50%).

![Meta-analysis of single laboratory biomarkers in PE (both EOPE and LOPE). Legend: (**1**) activin-A; (**2**) ADAM-12; (**3**) α fetoprotein; (**4**) α-1-macroglobulin; (**5**) anti-CD63 (GP53, lysosomal secretion); (**6**) chemerin; (**7**) C-reactive protein; (**8**) cystatin C; (**9**) endoglin; (**10**) E-selectin; (**11**) fetal DNA; (**12**) fetal hemoglobin (ratio); (**13**) fibronectin; (**14**) free β-hCG; (**15**) free leptin index; (**16**) GRP78 (glucose regulated protein) ratio C-term/full length; (**17**) Htr-A1 (High-Temperature Requirement A1); (**18**) inhibin-A; (**19**) NGAL (neutrophil gelatinase-associated lipocalin); (**20**) PAPP-A; (**21**) PBMC (peripheral blood mononuclear cell) miRNA; (**22**) PlGF; (**23**) PP-13; (**24**) P-selectin; (**25**) soluble endoglin; (**26**) sFLT/PlGF ratio; (**27**) sFlt-1; (**28**) sVEGFR-1 (vascular endothelial growth factor); (**29**) TNF-R1 (tumor necrosis factor receptor). PE: Pre-eclampsia; EOPE: early-onset PE; LOPE: late-onset PE.](ijms-16-23035-g004){#ijms-16-23035-f004}

![Summary of receiver operating characteristics curve of single laboratory biomarkers in PE (both EOPE and LOPE).](ijms-16-23035-g005){#ijms-16-23035-f005}

2.2. Early-Onset PE {#sec2dot2-ijms-16-23035}
-------------------

In the group of studies which categorized EOPE separately (*n* = 17), the pooled sensitivity of all single biomarkers was 0.37 (95% CI 0.32--0.41, I^2^ 82.4%) with a specificity of 0.88 (95% CI 0.87--088, I^2^ 98.8%). The area under the SROC was 0.794 (SE 0.05). The pooled sensitivity, specificity and area under the SROC of the separate meta-analyses of PAPP-A, PlGF and PP-13 are shown in [Table 2](#ijms-16-23035-t002){ref-type="table"}.

2.3. Late-Onset PE {#sec2dot3-ijms-16-23035}
------------------

In late-onset PE, (*n* = 14), the pooled sensitivity of all single biomarkers was 0.22 (95% CI 0.19--0.25, I^2^ 82.2%) with a specificity of 0.89 (95% CI 0.88--089, I^2^ 97.4%). The area under the SROC was 0.763 (SE 0.106). The pooled sensitivity, specificity and area under the SROC of the separate meta-analyses of PAPP-A is shown in [Table 2](#ijms-16-23035-t002){ref-type="table"}.

2.4. Combination of Biomarkers {#sec2dot4-ijms-16-23035}
------------------------------

From 13 studies, we extracted a pooled sensitivity of 0.43 (95% CI 0.41--0.46, I^2^ 95.8) and a pooled sensitivity of 0.91 (95% CI 0.90--0.91, I^2^ 98.3) and an area under the SROC of 0.893 (SE 0.03) for a combination model of clinical characteristics, laboratory biomarkers and/or uterine artery Doppler pulsatility index (UA-PI). The forest plot and SROC of these studies are shown in [Figure 6](#ijms-16-23035-f006){ref-type="fig"} and [Figure 7](#ijms-16-23035-f007){ref-type="fig"}, respectively.

![Meta-analysis of combination of laboratory and clinical makers in PE (both EOPE and LOPE). Legend: (**1**) PAPP-A, AFP, uE3, hCG (total or free β), inhibin-A; (**2**) mean PI + activin-A; (**3**) PlGF/sEng-ratio; (**4**) PAPP-A and free leptin index; (**5**) PP-13, UA-PI, AIx-75 (measure of arterial stiffness); (**6**) cystatin-C, CRP, uterine artery resistance index; (**7**) HbF ratio and A1M; (**8**) activin-A, inhibin-A, PlGF and UA-PI; (**9**) African American race, systolic blood pressure, BMI, education level, ADAM12, PAPP-A, PlGF; (**10**) BMI, education mother and HtrA1; (**11**) maternal characteristics, PlGF; (**12**) maternal characteristics, ADAM12; (**13**) maternal characteristics, PlGF; (**14**) sFLT-1, PlGF, PAPP-A, inhibin A, BMI, MAP; (**15**) PlGF, MAP, BMI, high fruit intake, uterine artery Doppler resistive index (UA-RI) \* validation cohort; (**16**) PlGF, MAP, BMI, high fruit intake, UA-RI \* training cohort.](ijms-16-23035-g006){#ijms-16-23035-f006}

![Summary of receiver operating characteristics curve of combination model of laboratory and makers in PE (both EOPE and LOPE).](ijms-16-23035-g007){#ijms-16-23035-f007}

ijms-16-23035-t002_Table 2

###### 

Meta-analyses of single laboratory biomarkers.

  All PE                Pooled Sensitivity (95% CI)   Pooled Specificity (95% CI)   Area Under SROC (SE)   EOPE                  Pooled Sensitivity (95% CI)   Pooled Specificity (95% CI)   Area Under SROC (SE)   LOPE               Pooled Sensitivity (95% CI)   Pooled Specificity (95% CI)   Area Under SROC (SE)
  --------------------- ----------------------------- ----------------------------- ---------------------- --------------------- ----------------------------- ----------------------------- ---------------------- ------------------ ----------------------------- ----------------------------- ----------------------
  ADAM-12 (*n* = 3)     0.26 (021--0.32)              0.84 (0.82--0.86)             0.671 (0.093)          ADAM-12 (*n* = 3)     \-                            \-                            \-                     \-                 \-                            \-                            \-
  Inhibin-A (*n* = 5)   0.32 (0.25--0.39)             0.90 (0.89--0.91)             0.957 (0.046)          Inhibin-A (*n* = 5)   \-                            \-                            \-                     \-                 \-                            \-                            \-
  PAPP-A (*n* = 14)     0.30 (0.29--0.32)             0.92 (0.92--0.92)             0.744 (0.071)          PAPP-A (*n* = 4)      0.26 (0.19--0.34)             0.90 (0.89--0.90)             0.907 (0.150)          PAPP-A (*n* = 4)   0.19 (0.14--0.24)             0.89 (0.89--0.90)             0.781 (0.173)
  PlGF (*n* = 8)        0.65 (0.63--0.67)             0.89 (0.89--0.89)             0.849 (0.068)          PlGF (*n* = 3)        0.37 (0.27--0.48)             0.79 (0.78--0.81)             0.796 (0.179)          \-                 \-                            \-                            \-
  PP-13 (*n* = 9)       0.37 (0.33--0.41)             0.88 (0.87-0.89)              0.882 (0.0450)         PP-13 (*n* = 9)       0.59 (0.48--0.69)             0.92 (0.91--0.93)             0.898 (0.064)          \-                 \-                            \-                            \-

3. Discussion {#sec3-ijms-16-23035}
=============

There is extensive literature on biomarkers in relation to PE and despite our focused strategy, we identified 401 biomarkers from the included publications. We then conducted a systematic review and meta-analyses using studies where we were able to extract comparable data for AUC and with more than two studies for each biomarker.

We examined single biomarkers in research conducted with different study cohorts, *i.e*., EOPE, LOPE or PE in general. Five biomarkers were highlighted: ADAM-12, inhibin-A, PAPP-A, PlGF and PP-13. ADAM12 is part of the ADAM protein family, which are involved in cell-to-cell and cell-to-matrix interactions in neural and muscle development as well as fertilization \[[@B51-ijms-16-23035],[@B52-ijms-16-23035],[@B53-ijms-16-23035]\]. PAPP-A is part of the first trimester Down's syndrome screening test and is a large zinc glycoprotein produced by placental trophoblasts \[[@B54-ijms-16-23035]\]. PlGF and sFLT are both angiogenic factors. PlGF is a polypeptide growth factor mainly expressed in placental trophoblasts and regulate the early development of placental villi \[[@B55-ijms-16-23035]\] while sFLT induces endothelial cell dysfunction \[[@B56-ijms-16-23035]\].

Prediction models utilizing a combination of biomarkers and clinical parameters improved the predictive value in studies examining PE (without distinction of EOPE and LOPE) with an area under the SROC of 0.893. However, the majority of combined models include evaluation of clinical history or assessment of uterine artery Doppler waveforms. This limits the potential of solely using laboratory-based biomarkers.

A limitation of this study is that our search strategy lead to significant number of missed articles that were found subsequently by other means, such as through the reference lists of articles that have been already identified. This may be due to our limited search terms and the wide variation in terminology used for studies on PE. Previous meta-analyses on early pregnancy biomarkers for PE have concentrated on either biochemical markers alone \[[@B42-ijms-16-23035]\] or in combination with ultrasound indices \[[@B57-ijms-16-23035],[@B58-ijms-16-23035],[@B59-ijms-16-23035]\].

Due to the low population prevalence of PE, despite \>200 studies on candidate biomarkers in the literature, none (nor any combination) have been identified with specificity and sensitivity that are useful for clinical practice \[[@B60-ijms-16-23035]\]. The systematic review from the World Health Organization (WHO) concluded that there is no cost effective or reliable screening test (clinical, biophysical, or biochemical) for PE \[[@B61-ijms-16-23035]\]. Perhaps this finding reflects that different types of biomarkers could point to different preventative strategies. For example, pregnancies associated with raised ADAM levels may need to be treated with aspirin, while those linked to raised PlGF levels may need to be treated with calcium.

The low predictive values using a single biomarker may be due to the heterogeneity between most studies such that we were unable to extract comparable data. Despite using the International Society for the study of Hypertension (ISSHP) definition in our review, there is a wide variation in the clinical manifestations and categorization of PE, such as early or late gestation, maternal or placental disease and mild or severe degree of PE. These could have introduced additional variability between the studies. Furthermore, many studies were conducted using different biomarkers, study population and definition of PE phenotype, *i.e.*, EOPE, LOPE or PE as one entity. We identified 147 articles but only 36 of these could be included in the meta-analyses. For each biomarker analyzed, the number of studies was even lower.

Many publications used PE, without sub-classification into EOPE and LOPE. This resulted in a poorly defined phenotype of PE which may further contribute to the low predictive value in these studies. As EOPE and LOPE have distinct and different pathogenesis mechanisms, it is likely that they are characterized by different biomarkers. Therefore, it is important to stratify study populations appropriately for accurate identification of biomarkers.

A possible source of bias arises from the over-representation of case-control studies in the reviewed literature. Furthermore, some studies were only conducted in women at high-risk of developing PE. Biomarkers which only have a high predictive value in EOPE may be another cause of overestimation. On the other hand, it is difficult to conduct studies focusing on LOPE as the phenotype is generally less severe than EOPE.

A well-designed study for biomarkers to predict PE in early pregnancy should be conducted in clearly defined populations, such as those with EOPE. The classic WHO screening criteria by Wilson and Jungner \[[@B62-ijms-16-23035]\] can be adapted for biomarker studies \[[@B63-ijms-16-23035],[@B64-ijms-16-23035]\]. These include: clearly defined clinical population and setting for use, set inclusion and/or exclusion criteria, focused outcome of interest, prospective specimen collection, aim for positive biomarker results in case and negative biomarker results in control, random selection of case and control subjects, accurate definition of true positive and true negative rates, clinically acceptable minimal test performance, favourable comparison with current risk stratification strategy, defined procedures for sample collection, processing, storage and retrieval, blind sampling, consideration of null hypothesis and alternative hypotheses, adequate sample size and that there is a policy present for early termination of the study if appropriate.Identification of women at risk of PE pre-eclampsia is the first step to effective intervention and prevention. However, currently there are no reliable biomarker tests for PE that have been accepted for wide clinical use and some countries have banned the use of biomarker screening in early gestation due to the possibility of inaccurate predictive test and its ethical implications. It is vital to develop a screening tool which is clinically relevant due to the serious consequences of incorrect risk stratification and inappropriate medication or pregnancy surveillance.

4. Methods {#sec4-ijms-16-23035}
==========

4.1. Studies {#sec4dot1-ijms-16-23035}
------------

We searched MEDLINE, EMBASE, Cochrane and ISI web of science from inception to 31st January 2015 using a combination of search terms with synonyms related to pre-eclampsia ("preeclampsia", "pre-eclampsia", "EPH", "pregnancy toxemia", "edema-proteinura-hypertension gestos", "PE"), biomarkers ("biological markers", "biomarker", "biological markers", "laboratory markers", "proteomics", "metabolomics", "surrogate endpoint", "surrogate end point"), and first trimester pregnancy ("early pregnancy", "first trimester pregnancy", "pregnancy trimester, first", "first pregnancy trimester", "first trimester", "early placental phase"). There were no limitations made on publication date or patient sample size. We excluded publications which were not in English. Animal studies were not included.

4.2. Study Selection {#sec4dot2-ijms-16-23035}
--------------------

Two independent reviewers (Pensée Wu and Caroline van den Berg) screened the title, abstract and key words of each article and made a record of the study design, biomarker type, and test period during pregnancy and study outcome. We included observational studies (cohort, cross-sectional and case-control) which assessed tests performed in the first or early second trimester of pregnancy for predicting pre-eclampsia in unselected women. The outcome definitions were as described in the definition of PE from International Society for the study of Hypertension in Pregnancy (ISSHP).\[[@B9-ijms-16-23035]\] Comments, editorials, case series (as defined by the authors of the studies) or reports were excluded, as were biomarker tests performed after 20 weeks of gestation. Genetic markers were not included as they require a different methodological approach and meta-analytic techniques. Reviews were included in the original search, to check for additional references.

4.3. Quality Assessment {#sec4dot3-ijms-16-23035}
-----------------------

An adapted version of the Quality Assessment of Diagnostic Accuracy Studies (QUADAS-2) tool was used to determine the methodological quality of the selected studies as not all items of the tools were relevant to our review \[[@B65-ijms-16-23035],[@B66-ijms-16-23035]\]. Summary scores were not calculated as their interpretation is difficult and may be potentially misleading \[[@B67-ijms-16-23035]\].

4.4. Data Extraction and Synthesis {#sec4dot4-ijms-16-23035}
----------------------------------

We extracted the study outcome measures which were shown in the articles (odds ratio, risk ratio, area under the curve (AUC), sensitivity and specificity). In multiple or duplicate publication of the same data set, we used the most complete or the most recent study. To perform the meta-analyses we only used studies where a sensitivity and specificity was reported. We performed these meta-analyses separately for the three different outcomes: PE, early-onset PE (EOPE, before 34 weeks of gestation) and late-onset PE (LOPE, after 34 weeks of gestation). Studies that used biomarkers in combination with clinical parameters were analyzed separately.

Meta-DiSc (version 1.4; Zamora *et al.*, Madrid, Spain) \[[@B68-ijms-16-23035]\] was used for statistical analyses. A pooled sensitivity and specificity was calculated, as well as a Summary of Receiver Operating Characteristics Curve (SROC). Raw data were used from each study, as adjustments for confounding effects varied between different studies. The inverse variance of the study was used to determine the weighting of studies in the meta-analyses. The random effects model was chosen due to the expected clinical and statistical heterogeneity among the studies. We assessed the heterogeneity of the results among studies through visual examination of Forest plots of AUC's, and using the I^2^ test \[[@B69-ijms-16-23035]\]. For all effect estimates, a value of *p \<* 0.05 was considered to be statistically significant.

5. Conclusions {#sec5-ijms-16-23035}
==============

We found that PlGF was best at predicting EOPE as a single biomarker. However, a combination model performed better than a single biomarker if studying PE as a single entity. A combination model including clinical and uterine artery Doppler assessments, negates the attraction of using a laboratory-based biomarker(s) prediction strategy.

Despite multiple potential biomarkers for PE, the efficacy of these markers has been inconsistent between different studies. The IMPROvED (IMproved PRegnancy Outcomes by Early Detection) study is an international multicentre study screening 5000 women in five European countries with the aim of developing a clinically robust predictive blood test for PE, utilising novel metabolite and protein biomarkers \[[@B60-ijms-16-23035]\]. We hope our study will contribute towards the ultimate goal of identifying the best predictive marker(s) and improve the management of women destined to develop PE.

The IMPROvED consortium has arisen from the IMPROvED project which has received funding from the European Union's Seventh Framework Programme for research, technological development and demonstration under grant agreement N° 310806.
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